{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-019198","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2023-07-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.582253+00:00","generated_at":"2026-06-13T13:25:52.870909+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"SAB Biotherapeutics shareholders elect Spragens and Link as Class II directors, ratify auditor","bullets":["Shareholders elected Jeffrey G. Spragens and David Link as Class II directors for three-year terms expiring at 2026 annual meeting.","Appointment of Mayer Hoffman McCann P.C. as independent auditor for FY 2023 ratified with 37.25M votes for, 33K against.","Over 37.5M shares voted, representing 74.45% of outstanding shares, constituting a quorum."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-019198","json":"https://secwatch.observer/filing/0001437749-23-019198.json","markdown":"https://secwatch.observer/filing/0001437749-23-019198.md","text":"https://secwatch.observer/filing/0001437749-23-019198.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923019198/0001437749-23-019198-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923019198/sabs20230629c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T13:25:52.870909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"72e579f9635559b6efb6ceac7279fc95d8212afa","claim":"SAB Biotherapeutics, Inc. shareholders approved Ratify the appointment of Mayer Hoffman McCann P.C. as independent registered public accounting firm at the 2023-06-29 meeting.","evidence_excerpt":"Proposal 2: Ratify the appointment of Mayer Hoffman McCann P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 Votes For Votes Against Abstentions 37,253,986 33,433 235,486","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923019198/0001437749-23-019198-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-29"}],"fact_type":"shareholder_vote"},{"claim_id":"acaf5cea150ea30694fc1d10fd56a9e733191849","claim":"SAB Biotherapeutics, Inc. shareholders approved Election of two Class II directors at the 2023-06-29 meeting.","evidence_excerpt":"Proposal 1: Election of two Class II directors Director Votes For Withheld Broker Non-Votes Jeffrey G. Spragens 30,399,580 403,139 6,720,186 David Link 30,402,160 400,559 6,720,186","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000143774923019198/0001437749-23-019198-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-29"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}